A Phase 3 interventional study of Dapagliflozin and Placebo in Heart Failure With Preserved Ejection Fraction, sponsored by AstraZeneca. Completed at 348 sites in 20 countries. Open to participants aged 40 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-07-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.
Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 3rd largest by enrollment, is the only one that started in 2018, is one of 16 in phase 3, and was the 5th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 12+
Yale University · Sites in United States
Ages 18–85 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 40+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 40 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 20 · Phase 4 22
First in 2015; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6,263 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 100 across the 59 interventional studies. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 59 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
64 studies in Heart Failure by AstraZeneca: 6 open now, 8 under way, 3 of them phase 3. Of 54 finished, 14 (26%) have results posted.
Among the 64 studies in Heart Failure by AstraZeneca, this one is the 4th largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2018, is one of 15 in phase 3, and was the 23rd registered.
AstraZeneca’s Heart Failure studies by the year they started, since 1999.
4 of the studies testing dapagliflozin in Heart Failure that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06304857Phase 34th Military Clinical Hospital with Polyclinic, PolandCardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL | 2026-12-31 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06578520Fundación para la Investigación del Hospital Clínico de ValenciaEffect of the Use of Dapagliflozin in Patients With Refractory Heart Failure | 2026-12-01 |
| NCT06762964Mayo ClinicCAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation | 2027-02 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies testing dapagliflozin in Heart Failure, from their registry updates:
Among AstraZeneca’s 64 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.
This is an international, multicentre, parallel-group, event-driven, randomised, double-blind study in patients with HFpEF, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death and heart failure events (hospitalisations for HF or urgent HF visits). Adult patients aged ≥40 years with HFpEF (LVEF >40% and evidence of structural heart disease) and New York Heart Association (NYHA) class II-IV who are eligible according to the inclusion/exclusion criteria will be randomised in a 1:1 ratio to receive either dapagliflozin 10 mg or placebo. Both out-patients and in-patients hospitalised for heart failure and off intravenous heart failure-therapy for 24 hours can be randomised. It is estimated that approximately 11000 patients at approximately 400-500 sites in 20-25 countries will need to be enrolled to reach the target of approximately 6100 randomised patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Further details regarding inclusion criteria 4-6 may apply.
Exclusion Criteria:
Further exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be randomized 1:1 to either dapagliflozin or placebo.
Drug: Dapagliflozin
Placebo matching dapagliflozin.
Drug: Placebo
10 mg tablets given once daily, per oral use.
Also known as: Forxiga TM, Farxiga TM
Placebo matching dapagliflozin 10 mg
Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.
Dual primary efficacy Primary endpoint analysed in all patients randomised (Full analysis set). The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.
Time frame: Up to 42.1 months
Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation
Dual primary efficacy Primary endpoint analysed in all patients randomised with LVEF \< 60% at baseline. The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.
Time frame: Up to 42.1 months
Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit)
Secondary efficacy Total number of heart failure events (first and recurrent) and cardiovascular death, analysed in all randomized patients. The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.
Time frame: Up to 42.1 months
Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit) for LVEF <60% Subpopulation
Secondary efficacy Total number of heart failure events (first and recurrent) and cardiovascular death, analysed in all randomized patients with LVEF \< 60% at baseline The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.
Time frame: Up to 42.1 months
Change From Baseline in the KCCQ Total Symptom Score at 8 Months
KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ Total Symptom Score incorporates the symptom domains into a single score. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Time frame: Baseline and 8 months or death before 8 months
Subjects Included in the Endpoint of Cardiovascular Death
Secondary efficacy The analysis was assessed on Full Analysis Set, including deaths occurring on or prior to Primary Analysis Censoring Date.
Time frame: Up to 42.1 months
Subjects Included in the Endpoint of All-cause Mortality
Secondary efficacy The analysis was assessed on Full Analysis Set, including deaths occurring on or prior to Primary Analysis Censoring Date.
Time frame: Up to 42.1 months
| Milestone | Dapa 10 mg | Placebo |
|---|---|---|
| Started | 3131 | 3132 |
| Completed | 3121 | 3121 |
| Not completed | 10 | 11 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Withdrawal by subject | 8 | 10 |
Dual primary efficacy Primary endpoint analysed in all patients randomised (Full analysis set). The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.
| Participants | Dapa 10 mg | Placebo |
|---|---|---|
| Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. | 512 | 610 |
Dual primary efficacy Primary endpoint analysed in all patients randomised with LVEF \< 60% at baseline. The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.
| Participants | Dapa 10 mg | Placebo |
|---|---|---|
| Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation | 381 | 440 |
Secondary efficacy Total number of heart failure events (first and recurrent) and cardiovascular death, analysed in all randomized patients. The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.
| Number of events | Dapa 10 mg | Placebo |
|---|---|---|
| Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit) | 815 | 1057 |
Secondary efficacy Total number of heart failure events (first and recurrent) and cardiovascular death, analysed in all randomized patients with LVEF \< 60% at baseline The analysis was assessed on Full Analysis Set, including events occurring on or prior to Primary Analysis Censoring Date.
| Number of events | Dapa 10 mg | Placebo |
|---|---|---|
| Events Included in the Composite Endpoint of CV Death or Recurrent Heart Failure Event (Hospitalization Due to Heart Failure or Urgent Heart Failure Visit) for LVEF <60% Subpopulation | 605 | 782 |
KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ Total Symptom Score incorporates the symptom domains into a single score. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
| Scores on a scale | Dapa 10 mg | Placebo |
|---|---|---|
| Change From Baseline in the KCCQ Total Symptom Score at 8 Months | 8.3 ± 20.3 | 5.2 ± 21.1 |
Secondary efficacy The analysis was assessed on Full Analysis Set, including deaths occurring on or prior to Primary Analysis Censoring Date.
| Participants | Dapa 10 mg | Placebo |
|---|---|---|
| Subjects Included in the Endpoint of Cardiovascular Death | 231 | 261 |
Secondary efficacy The analysis was assessed on Full Analysis Set, including deaths occurring on or prior to Primary Analysis Censoring Date.
| Participants | Dapa 10 mg | Placebo |
|---|---|---|
| Subjects Included in the Endpoint of All-cause Mortality | 497 | 526 |
Collected over [All-cause mortality]: From randomization until end of study, up to 42.2 months. [Serious AE and other AE] From first dose until end of study, up to 42.2 months.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapa 10 mg | 510/3,131 (16.3%) | 1,454/3,126 (46.5%) | 464/3,126 (14.8%) |
| Placebo | 533/3,132 (17%) | 1,508/3,127 (48.2%) | 485/3,127 (15.5%) |
| Event | Dapa 10 mg | Placebo |
|---|---|---|
| Cardiac failureCardiac disorders | 308/3126 | 377/3127 |
| Covid-19Infections and infestations | 183/3126 | 144/3127 |
| PneumoniaInfections and infestations | 113/3126 | 106/3127 |
| Covid-19 pneumoniaInfections and infestations | 86/3126 | 89/3127 |
| Cardiac failure congestiveCardiac disorders | 63/3126 | 82/3127 |
| Ischaemic strokeNervous system disorders | 70/3126 | 65/3127 |
| Atrial fibrillationCardiac disorders | 69/3126 | 57/3127 |
| Acute myocardial infarctionCardiac disorders | 63/3126 | 63/3127 |
| Cardiac failure acuteCardiac disorders | 57/3126 | 63/3127 |
| Acute kidney injuryRenal and urinary disorders | 54/3126 | 63/3127 |
| Event | Dapa 10 mg | Placebo |
|---|---|---|
| Cardiac failureCardiac disorders | 179/3126 | 214/3127 |
| Urinary tract infectionInfections and infestations | 113/3126 | 112/3127 |
| HypertensionVascular disorders | 84/3126 | 102/3127 |
| Atrial fibrillationCardiac disorders | 86/3126 | 61/3127 |
| HypotensionVascular disorders | 69/3126 | 61/3127 |
| Age, Continuous(Years) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| Mean | 71.8 ± 9.6 | 71.5 ± 9.5 | 71.7 ± 9.6 |
| Age, Customized(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| <= 50 | 85 | 74 | 159 |
| > 50 | 3046 | 3058 | 6104 |
| Age, Customized(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| <= 65 | 743 | 761 | 1504 |
| > 65 | 2388 | 2371 | 4759 |
| Age, Customized(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| <= 65 | 743 | 761 | 1504 |
| >65 - 75 | 1184 | 1228 | 2412 |
| > 75 | 1204 | 1143 | 2347 |
| Sex: Female, Male(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| Female | 1364 | 1383 | 2747 |
| Male | 1767 | 1749 | 3516 |
| Ethnicity (NIH/OMB)(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 632 | 598 | 1230 |
| Not Hispanic or Latino | 2499 | 2534 | 5033 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| White | 2214 | 2225 | 4439 |
| Black or African American | 81 | 78 | 159 |
| Asian | 630 | 644 | 1274 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| American Indian or Alaska Native | 93 | 96 | 189 |
| Other | 113 | 89 | 202 |
| Prior HF Hospitalization(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| Yes | 1270 | 1269 | 2539 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 348 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Aug 2018 to primary completion in Mar 2022, 43 months.
Results were first posted in Jul 2023, 1 year 3 months after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 43 months is above that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin